Clinical trial · Observational
Enhancing Shared Decision-Making in Metastatic Breast Cancer (Qualitative Study)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Develop a Metastatic Breast Cancer (MBC)-specific electronic Treatment Plans (TP). Phase 1: Aim 1a: Patient interviews along with navigator, nurse, and physician focus group discussions will be used to identify factors that influence decision-making in treatment selection and the optimal approach for sharing information about prognosis and guideline-based care. Identify decisional needs for Shared Decision Making (SDM) in MBC. Investigators will conduct semi-structured interviews/discussion groups with patients, navigators, nurses, and physicians to elements important to decision-making. Phase 2: Aim 1b: Develop MBC-specific TP. Investigators will build upon Aim1a to systematically develop the TP intervention using the Ottawa Decision Support Framework. Investigators will test the TPs with 5 patients and conduct qualitative investigations to refine the TP using an iterative process. Phase 3:Further explore decision-making related to reducing amount of chemotherapy for patients with good prognosis.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Decision Making ,Shared | — | UNRESOLVED | — |
| De-escalation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Qualitative Interview or Focus group discussions | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (8)
- label
- Metastatic Breast Interview Participants - Shared Decision Making
- description
- Metastatic Breast Patient Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
- interventionNames
- Other: Qualitative Interview or Focus group discussions
- label
- Early Stage Breast Interview Participants - Shared Decision Making
- description
- Early Stage Breast Patient Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
- interventionNames
- Other: Qualitative Interview or Focus group discussions
- label
- Provider Focus Group -Shared Decision Making
- description
- Clinic Provider Participants will participate in a focus group on the topic of Shared Decision Making. This will be a one time, focus group interview with a trained moderator.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Patient Criteria (Phase I,II,III): Inclusion Criteria: * 1\. Women with age ≥ 18 * 2\. Presence of Metastatic Breast Cancer or Early Stage Breast Cancer * 3\. Patients may be receiving any line and type of therapy including both standard of care and clinical trials. Exclusion Criteria: * 1\. Patient who are not able to read and/or speak English * 2\. Patients with a life expectancy less than 3 months * 3\. Patients unable to provide informed consent * 4\. Men Patient Advocates (Phase III) Inclusion criteria: 1\. Providers who are self-identified patient advocates working with breast cancer researchers Exclusion criteria: 1. None Sampling: We will conduct interviews with 10-20 patient advocates for phase 3 of this project. Provider (navigator, nurse, physician) (Pjhase I, III) Inclusion criteria: 2. Providers who have direct contact with breast cancer patients Exclusion criteria: 2\. None
References
Publications (1)
- DERIVEDRocque GB, Andrews C, Lawhon VM, Ingram SA, Frazier RM, Smith ML, Wagner LI, Zubkoff L, Wallner LP, Wolff AC. Physician Perspectives on Reducing Curative Cancer Treatment Intensity for Populations Underrepresented in Clinical Trials. Oncologist. 2022 Dec 9;27(12):1067-1073. doi: 10.1093/oncolo/oyac191. PMID 36215065